Nerve growth factor fusion protein, preparation method and use thereof
AssigneeStaidson (Beijing) Biopharmaceuticals Co., Ltd.
InventorsQingshuang Zhang, Lei Ma, Ming Liu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of biopharmaceuticals and provides a nerve growth factor (NGF) fusion protein and a preparation method and use thereof. The fusion protein has a general formula represented by A-B or A-L-B, wherein A is a nerve growth factor, L is a linker peptide, and B is an Fc moiety of IgG, or an analogue of the Fc moiety of IgG, or a fragment of the Fc moiety of IgG. The fusion protein of the present disclosure has the following advantages over a wild-type NGF: higher biological activity, a half-life extended more than 17 times, greatly reduced administration frequency, and significantly increased efficacy.
Claims9
A nerve growth factor fusion protein, comprising a general formula A-B or A-L-B, wherein:
- A is a human nerve growth factor,
- L is a linker peptide, and
- B is an Fc moiety of IgG1, a mutant of the Fc moiety of IgG1, or a fragment of the Fc moiety of IgG1, wherein the mutant of the Fc moiety comprises a site mutation associated with antibody dependent cell-mediated cytotoxicity (ADCC)/complement dependent cytotoxicity (CDC) activity, or a deglycosylation mutation;
- wherein the human nerve growth factor comprises F12E with reference to the amino acid position set forth in mature wild-type human nerve growth factor.
A pharmaceutical composition, comprising a pharmaceutically acceptable excipient, and a nerve growth factor fusion protein;
- wherein the nerve growth factor fusion protein comprises a general formula A-B or A-L-B, wherein A is a human nerve growth factor, L is a linker peptide, and B is an Fc moiety of IgG1, a mutant of the Fc moiety of IgG1, or a fragment of the Fc moiety of IgG1, wherein the mutant of the Fc moiety comprises a site mutation associated with antibody dependent cell-mediated cytotoxicity (ADCC)/complement dependent cytotoxicity (CDC) activity, or a deglycosylation mutation:
- wherein the human nerve growth factor comprises F12E with reference to the amino acid position set forth in mature wild-type human nerve growth factor.
Dependencies are inferred from the claim text.